|
Uterine Corpus Sarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
SMARCA4-deficient Uterine Sarcoma and Undifferentiated Endometrial Carcinoma are Distinct Clinicopathologic Entities.
|
31567195 |
2020 |
|
Colitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Together, our results establish that BRG1 may represent an autophagy checkpoint that is pathogenetically linked to colitis and is therefore likely a potential therapeutic target for disease intervention.
|
31601814 |
2019 |
|
Esophageal Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
We highlight the relevance of SMARCA4 as a drug target in esophageal cancer using an engineered ESCC cell model harboring a SMARCA4 allele amenable to targeted proteolysis and identify SMARCA4-dependent cell models with low or absent SMARCA2 expression from additional tumor types.
|
31406271 |
2019 |
|
Hydrocephalus
|
0.010 |
Biomarker
|
disease |
BEFREE |
Macroscopic examination revealed a severe hydrocephalus and a decreased brain weight caused by the loss of Brg1.
|
31504276 |
2019 |
|
Kidney Failure, Acute
|
0.010 |
Biomarker
|
disease |
BEFREE |
In the present study we investigated the role of BRG1, a chromatin remodeling protein, in AKI with a focus on its regulation of IL-33 expression in endothelial cells.
|
31228616 |
2019 |
|
Leukemia, T-Cell
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We reveal that HTLV-1 cell lines and adult T-cell leukemia (ATL) cells harbor high levels of BRG1.
|
31142665 |
2019 |
|
Lymphoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Correction to: BRG1 regulation by miR-155 in human leukemia and lymphoma cell lines.
|
31350682 |
2019 |
|
Mental Retardation
|
0.010 |
Biomarker
|
disease |
BEFREE |
X-linked α-thalassemia with mental retardation (ATRX) is a chromatin remodeling protein that belongs to the SWItch/sucrose non-fermentable (SWI2/SNF2) family of helicase/ATPases.
|
30649195 |
2019 |
|
Nasal Polyps
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our study found that H3K4me3 histone demethylase KDM2B (also known as JHDM1B) and transcriptional regulator Brg1 (also called SNF2-β or Smarca4) were significantly decreased in nasal mucosa of CRSwNP patients, and they were positively correlated.
|
31041569 |
2019 |
|
Neoplasms, Vascular Tissue
|
0.010 |
Biomarker
|
group |
BEFREE |
These include gene fusions in vascular neoplasms (FOSB, CAMTA1 and TFE3), round cell sarcomas (BCOR, DUX4 and WT1), and fibroblastic/myofibroblastic tumors (STAT6, ALK and Pan-TRK); amplifications in well-differentiated and dedifferentiated liposarcomas (MDM2 and CDK4); and deletions in several aggressive neoplasms (SMARCB1 and SMARCA4).
|
30382607 |
2019 |
|
Ureteral obstruction
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Endothelial-specific deletion of Brahma-related gene 1 (BRG1) assuages unilateral ureteral obstruction induced renal injury in mice.
|
31349970 |
2019 |
|
Synovial Cyst
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We found that RGCs treated with HG exhibited a low expression level of Brg1 compared with untreated RGCs.
|
31101335 |
2019 |
|
Obstructive nephropathy
|
0.010 |
Biomarker
|
disease |
BEFREE |
In conclusion, we propose that epigenetic regulation of endothelial function by BRG1 may play an active role in ON pathogenesis.
|
31349970 |
2019 |
|
Esophageal carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We highlight the relevance of SMARCA4 as a drug target in esophageal cancer using an engineered ESCC cell model harboring a SMARCA4 allele amenable to targeted proteolysis and identify SMARCA4-dependent cell models with low or absent SMARCA2 expression from additional tumor types.
|
31406271 |
2019 |
|
Liposarcoma, Dedifferentiated
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
These include gene fusions in vascular neoplasms (FOSB, CAMTA1 and TFE3), round cell sarcomas (BCOR, DUX4 and WT1), and fibroblastic/myofibroblastic tumors (STAT6, ALK and Pan-TRK); amplifications in well-differentiated and dedifferentiated liposarcomas (MDM2 and CDK4); and deletions in several aggressive neoplasms (SMARCB1 and SMARCA4).
|
30382607 |
2019 |
|
Impaired glucose tolerance
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
In contrast, removal of both Swi/Snf ATPase subunits, Brg1 and Brm, was necessary to compromise adult islet β-cell activity, which included whole-animal glucose intolerance, hyperglycemia, and impaired insulin secretion.
|
31201281 |
2019 |
|
Squamous cell carcinoma of esophagus
|
0.010 |
Biomarker
|
disease |
BEFREE |
We highlight the relevance of SMARCA4 as a drug target in esophageal cancer using an engineered ESCC cell model harboring a SMARCA4 allele amenable to targeted proteolysis and identify SMARCA4-dependent cell models with low or absent SMARCA2 expression from additional tumor types.
|
31406271 |
2019 |
|
Vascular Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
These include gene fusions in vascular neoplasms (FOSB, CAMTA1 and TFE3), round cell sarcomas (BCOR, DUX4 and WT1), and fibroblastic/myofibroblastic tumors (STAT6, ALK and Pan-TRK); amplifications in well-differentiated and dedifferentiated liposarcomas (MDM2 and CDK4); and deletions in several aggressive neoplasms (SMARCB1 and SMARCA4).
|
30382607 |
2019 |
|
Superficial ulcer
|
0.010 |
Biomarker
|
disease |
BEFREE |
Subsequently, all groups were subjected to a 5-day erosion cycle intercalating demineralization (1 min; 1% citric acid; pH = 3.5) and treatment with toothpaste slurries (2 min) of NaF, SnF2, F/Sn/Chitosan, F/CaSiO3/Na3PO4, and F/bioactive glass.
|
31800865 |
2019 |
|
Inflammatory Myofibroblastic Tumor
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
These include gene fusions in vascular neoplasms (FOSB, CAMTA1 and TFE3), round cell sarcomas (BCOR, DUX4 and WT1), and fibroblastic/myofibroblastic tumors (STAT6, ALK and Pan-TRK); amplifications in well-differentiated and dedifferentiated liposarcomas (MDM2 and CDK4); and deletions in several aggressive neoplasms (SMARCB1 and SMARCA4).
|
30382607 |
2019 |
|
Vascular calcification
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Consequently, our study demonstrates that Smarca4 is involved in hyperphosphorus-induced VC.
|
30973285 |
2019 |
|
Respiratory syncytial virus (RSV) infection in conditions classified elsewhere and of unspecified site
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Comparative cellular proteomic analysis revealed that SWI2/SNF2-related CREB-binding protein activator protein (SRCAP) was a candidate for the antiviral activity of LG2055 against RSV.
|
30886158 |
2019 |
|
Lymphadenopathy
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Most SMARCA4-DTS present with compressive and infiltrative chest masses with ill-defined necrotic lymphadenopathies.
|
30762113 |
2019 |
|
Malignant neoplasm of esophagus
|
0.010 |
Biomarker
|
disease |
BEFREE |
We highlight the relevance of SMARCA4 as a drug target in esophageal cancer using an engineered ESCC cell model harboring a SMARCA4 allele amenable to targeted proteolysis and identify SMARCA4-dependent cell models with low or absent SMARCA2 expression from additional tumor types.
|
31406271 |
2019 |
|
Retinal Dystrophies
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Retinal dystrophy in an individual carrying a de novo missense variant of SMARCA4.
|
30973214 |
2019 |